Lantheus Acquires Life Molecular Imaging from Life Healthcare

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

SHINE Technologies Acquires Lantheus' SPECT Business

January 2, 2026

Pharmaceuticals

SHINE Technologies has completed the acquisition of Lantheus' SPECT business, including the North Billerica, Massachusetts SPECT manufacturing facility and a portfolio of diagnostic radiopharmaceuticals (TechneLite, Cardiolite, NEUROLITE, Xenon Xe-133). SHINE named Michael Rossi CEO of SHINE SPECT USA, LLC and said the acquisition expands its nuclear medicine manufacturing capabilities and integrates with its Chrysalis Mo-99 production to strengthen isotope supply chain security.

Intelerad Acquires Life Image

September 15, 2022

Healthcare Services

Intelerad Medical Systems has acquired Life Image, combining two of the largest medical image exchange networks to create the world’s largest interoperable medical image exchange platform managing over 80 billion images. The acquisition advances Intelerad's strategy to eliminate physical media for image transfer, accelerate interoperability across EHRs/PACS/AI platforms, and expand capabilities for provider and research customers.

Ariceum Therapeutics Acquires Theragnostics Ltd.

June 1, 2023

Biotechnology

Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.

LifeNet Health Acquires HCM Medical

August 20, 2025

Biotechnology

LifeNet Health has acquired HCM Medical, a Netherlands‑based contract manufacturing organization (CMO) specializing in biologics and tissue‑processing technologies. The deal expands LifeNet Health's manufacturing capabilities in regenerative biologics — including xenograft platforms, antibiotic‑coated implants, and advanced sterilization — to accelerate global access to advanced therapies.